Login / Signup

Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.

Coraline DumenilMarie-Ange MassianiJennifer DumoulinViolaine GiraudSylvie LabruneThierry ChinetEtienne Giroux-Leprieur
Published in: PloS one (2018)
Our results suggest that nivolumab is not beneficial or safe for patients with PS 2 and symptomatic brain metastases.
Keyphrases
  • brain metastases
  • small cell lung cancer
  • single cell
  • cell therapy
  • oxidative stress
  • stem cells
  • young adults
  • mesenchymal stem cells